George Labban, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 26
- 6 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
26 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Labban’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
26 of 26 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C53848 · Current
Licensed to practise in California · since 2009 · expires 2027-02-28 · University of Damascus Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$153,749
Medicare paid this office $153,749 for 565 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 167 | $57,888 | $136 |
| Return visit (30+ min) | 364 | $52,130 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $15,262 | $105 |
| New patient visit (60+ min) | 68 | $10,928 | $161 |
| Short return visit (20+ min) | 96 | $6,670 | $61 |
See all 8 services
| Long return visit (40+ min) | 167 | $57,888 | $136 |
| Return visit (30+ min) | 364 | $52,130 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $15,262 | $105 |
| New patient visit (60+ min) | 68 | $10,928 | $161 |
| Short return visit (20+ min) | 96 | $6,670 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,490 | $155 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 111 | $2,331 | $15 |
| New patient visit (45+ min) | 14 | $1,744 | $125 |
Who their Medicare patients are
565 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 16% · Women 72% · Also on Medicaid 12% · Health risk score 1.65. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 62% · Diabetes 31% · Coronary heart disease 30% · Chronic kidney disease 24% · Atrial fibrillation 19% · Heart failure 18% · Depression 16% · COPD 13% · Stroke 9% · Dementia 7%.
The office billed $558,245, Medicare allowed $206,124 and paid $153,749; for 1,546 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 565 | 1,546 | 77 | 1.65 | $558,245 | $153,749 |
| 2023 | 551 | 1,392 | 77 | 1.74 | $514,037 | $146,822 |
| 2022 | 612 | 1,528 | 77 | 1.71 | $562,942 | $155,397 |
| 2021 | 599 | 1,645 | 76 | 1.73 | $461,708 | $166,381 |
| 2020 | 571 | 1,509 | 76 | 1.86 | $447,218 | $132,260 |
| 2019 | 598 | 2,096 | 76 | 1.89 | $360,706 | $176,258 |
| 2018 | 647 | 58,118 | 76 | 1.87 | $4,271,025 | $1,044,451 |
| 2017 | 664 | 136,937 | 76 | 1.88 | $9,642,713 | $2,142,334 |
| 2016 | 521 | 102,439 | 76 | 1.73 | $4,755,291 | $1,479,421 |
| 2015 | 476 | 131,547 | 76 | 1.79 | $4,329,140 | $1,445,047 |
| 2014 | 496 | 101,957 | 76 | 1.74 | $3,973,793 | $1,266,253 |
| 2013 | 506 | 102,588 | 76 | 1.80 | $4,926,145 | $1,743,411 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 185 | $57,404 | $121 |
| Return visit (30+ min) | 336 | $38,905 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $28,898 | $107 |
| New patient visit (60+ min) | 78 | $12,369 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,001 | $156 |
| Short return visit (20+ min) | 31 | $2,013 | $56 |
| New patient visit (45+ min) | 12 | $1,439 | $120 |
2022: 8 services
| Long return visit (40+ min) | 218 | $69,756 | $122 |
| Return visit (30+ min) | 374 | $42,539 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $17,490 | $93 |
| New patient visit (60+ min) | 102 | $16,571 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,674 | $178 |
| Short return visit (20+ min) | 31 | $2,273 | $54 |
| New patient visit (45+ min) | 18 | $2,038 | $113 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $1,653 | $34 |
2021: 9 services
| Long return visit (40+ min) | 212 | $65,438 | $122 |
| Return visit (30+ min) | 385 | $52,354 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $19,522 | $97 |
| New patient visit (60+ min) | 84 | $14,574 | $173 |
| New patient visit (45+ min) | 33 | $4,171 | $126 |
| Short return visit (20+ min) | 65 | $4,068 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,961 | $185 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $1,203 | $35 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $420 | $30 |
2020: 6 services
| Long return visit (40+ min) | 186 | $48,066 | $100 |
| Return visit (30+ min) | 333 | $36,962 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $22,743 | $96 |
| New patient visit (60+ min) | 100 | $15,131 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,778 | $180 |
| Short return visit (20+ min) | 60 | $2,755 | $40 |
2019: 7 services
| Long return visit (40+ min) | 199 | $60,423 | $96 |
| Return visit (30+ min) | 408 | $54,306 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $33,864 | $94 |
| New patient visit (60+ min) | 92 | $13,292 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,525 | $184 |
| Short return visit (20+ min) | 82 | $4,286 | $42 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $949 | $73 |
2018: 25 services
| Injection, pegfilgrastim, 6 mg | 13 | $108,425 | None |
| Return visit (30+ min) | 420 | $80,581 | $77 |
| Injection, denosumab, 1 mg | 26 | $67,939 | None |
| Long return visit (40+ min) | 187 | $53,165 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $32,337 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 36 | $19,903 | $149 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $18,036 | None |
| New patient visit (60+ min) | 80 | $12,665 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $10,973 | $180 |
| Short return visit (20+ min) | 132 | $9,790 | $53 |
| Injection, palonosetron hcl, 25 mcg | 18 | $8,347 | None |
| Injection of additional new drug or substance into vein | 29 | $4,578 | $18 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 217 | $4,528 | $9 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $3,624 | $71 |
| Injection of drug or substance under skin or into muscle | 57 | $3,456 | $18 |
| Administration of chemotherapy into vein, each additional hour | 17 | $2,246 | $32 |
| Drawing of blood for a medical problem | 12 | $2,144 | $97 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 24 | $1,909 | $32 |
| Irrigation of implanted venous access drug delivery device | 21 | $945 | $28 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $934 | $67 |
| Injection, ranitidine hydrochloride, 25 mg | 15 | $306 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $81 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $72 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $38 | None |
| Not otherwise classified, antineoplastic drugs | 14 | $23 | None |
2017: 38 services
| Injection, bevacizumab, 10 mg | 13 | $347,108 | None |
| Injection, pegfilgrastim, 6 mg | 35 | $293,545 | None |
| Injection, denosumab, 1 mg | 38 | $152,308 | None |
| Return visit (30+ min) | 398 | $98,062 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 78 | $48,101 | $144 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 23 | $38,693 | None |
| Long return visit (40+ min) | 154 | $38,270 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $29,849 | $93 |
| Injection, palonosetron hcl, 25 mcg | 43 | $19,720 | None |
| New patient visit (60+ min) | 106 | $19,643 | $185 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 69 | $13,659 | $31 |
| Short return visit (20+ min) | 142 | $12,430 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,387 | $180 |
| Injection of drug or substance under skin or into muscle | 113 | $10,364 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 287 | $9,833 | $10 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $9,760 | $67 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $7,215 | $76 |
| Injection, fosaprepitant, 1 mg | 11 | $5,481 | None |
| Injection of additional new drug or substance into vein | 49 | $5,045 | $23 |
| Administration of chemotherapy into vein, each additional hour | 43 | $4,924 | $28 |
| Administration of additional new drug or substance into vein using push technique | 18 | $3,925 | $64 |
| Drawing of blood for a medical problem | 13 | $3,625 | $101 |
| Injection, oxaliplatin, 0.5 mg | 11 | $3,456 | None |
| Not otherwise classified, antineoplastic drugs | 44 | $2,051 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,981 | $32 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $1,737 | $60 |
| Irrigation of implanted venous access drug delivery device | 22 | $1,329 | $25 |
| Injection, carboplatin, 50 mg | 17 | $1,289 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,215 | $71 |
| Injection, paclitaxel, 1 mg | 18 | $1,169 | None |
| Injection, fluorouracil, 500 mg | 12 | $714 | None |
| Infusion into a vein for hydration, each additional hour | 11 | $616 | $15 |
| Insertion of needle into vein for collection of blood sample | 68 | $241 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 19 | $189 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $166 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 52 | $93 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $59 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $47 | None |
2016: 37 services
| Injection, pegfilgrastim, 6 mg | 22 | $237,201 | None |
| Injection, denosumab, 1 mg | 26 | $131,543 | None |
| Return visit (30+ min) | 309 | $70,067 | $92 |
| Short return visit (20+ min) | 268 | $33,250 | $64 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $31,958 | None |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $30,785 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $25,579 | $91 |
| Long return visit (40+ min) | 92 | $17,797 | $129 |
| Injection, palonosetron hcl, 25 mcg | 31 | $16,366 | None |
| New patient visit (60+ min) | 80 | $14,791 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $11,226 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $10,986 | $31 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $9,874 | $77 |
| Injection of drug or substance under skin or into muscle | 71 | $8,928 | $24 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 241 | $8,690 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $6,944 | $64 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $6,261 | $64 |
| Administration of chemotherapy into vein, each additional hour | 27 | $3,709 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $2,775 | $71 |
| Administration of additional new drug or substance into vein using push technique | 12 | $2,603 | $63 |
| Injection of additional new drug or substance into vein | 33 | $2,439 | $23 |
| Biopsy of bone marrow | 13 | $2,180 | $168 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $2,001 | $57 |
| New patient visit (45+ min) | 11 | $1,672 | $152 |
| Injection, carboplatin, 50 mg | 20 | $1,564 | None |
| Injection, paclitaxel, 1 mg | 13 | $1,375 | None |
| Aspiration of bone marrow sample for diagnosis | 13 | $1,046 | $80 |
| Irrigation of implanted venous access drug delivery device | 15 | $778 | $24 |
| Infusion into a vein for hydration, each additional hour | 12 | $614 | $14 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $366 | None |
| Insertion of needle into vein for collection of blood sample | 73 | $268 | $3 |
| Injection, ranitidine hydrochloride, 25 mg | 23 | $162 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 38 | $154 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 36 | $84 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $80 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $40 | None |
| Unclassified drugs | 11 | $13 | None |
2015: 29 services
| Injection, pegfilgrastim, 6 mg | 21 | $294,277 | None |
| Return visit (30+ min) | 306 | $92,929 | $96 |
| Injection, denosumab, 1 mg | 19 | $85,991 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 18 | $61,168 | None |
| Administration of chemotherapy into vein, 1 hour or less | 43 | $44,654 | $140 |
| Short return visit (20+ min) | 214 | $31,649 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $28,671 | $92 |
| Long return visit (40+ min) | 96 | $20,217 | $133 |
| Injection, palonosetron hcl, 25 mcg | 22 | $20,153 | None |
| New patient visit (60+ min) | 87 | $16,283 | $187 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $16,152 | $31 |
| Injection of drug or substance under skin or into muscle | 50 | $11,936 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 220 | $10,235 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,034 | $174 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $8,990 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $6,238 | $64 |
| Administration of additional new drug or substance into vein using push technique | 12 | $3,947 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $3,583 | $72 |
| Administration of chemotherapy into vein, each additional hour | 23 | $3,477 | $28 |
| Injection of additional new drug or substance into vein | 28 | $3,291 | $23 |
| Injection, carboplatin, 50 mg | 13 | $1,502 | None |
| Irrigation of implanted venous access drug delivery device | 18 | $1,106 | $24 |
| Injection, ranitidine hydrochloride, 25 mg | 30 | $263 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 18 | $258 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $236 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $235 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 35 | $77 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $64 | None |
| Insertion of needle into vein for collection of blood sample | 17 | $56 | $3 |
2014: 32 services
| Injection, pegfilgrastim, 6 mg | 17 | $138,555 | None |
| Injection, denosumab, 1 mg | 16 | $81,432 | None |
| Return visit (30+ min) | 267 | $68,519 | $98 |
| Short return visit (20+ min) | 326 | $45,635 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 37 | $40,263 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $20,388 | $91 |
| Long return visit (40+ min) | 89 | $17,972 | $132 |
| New patient visit (60+ min) | 94 | $17,609 | $187 |
| Injection, palonosetron hcl, 25 mcg | 23 | $15,451 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $14,130 | $30 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $13,974 | $75 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 226 | $9,568 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $9,346 | $173 |
| Injection of drug or substance under skin or into muscle | 41 | $6,872 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $6,309 | $69 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $5,916 | $63 |
| Injection of additional new drug or substance into vein | 26 | $3,761 | $22 |
| Administration of chemotherapy into vein, each additional hour | 25 | $3,527 | $28 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $2,492 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,434 | $64 |
| Infusion into a vein for hydration, each additional hour | 16 | $2,269 | $15 |
| Aspiration of bone marrow sample for diagnosis | 15 | $1,758 | $110 |
| Biopsy of bone marrow | 13 | $1,659 | $128 |
| Irrigation of implanted venous access drug delivery device | 18 | $1,055 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $830 | $18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $200 | None |
| Injection, ranitidine hydrochloride, 25 mg | 18 | $183 | None |
| Insertion of needle into vein for collection of blood sample | 54 | $168 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 12 | $142 | None |
| Infusion, normal saline solution , 1000 cc | 21 | $118 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 15 | $68 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $67 | None |
2013: 43 services
| Injection, pegfilgrastim, 6 mg | 25 | $160,301 | None |
| Short return visit (20+ min) | 362 | $79,248 | $65 |
| Injection, denosumab, 1 mg | 13 | $64,534 | None |
| Administration of chemotherapy into vein, 1 hour or less | 78 | $55,661 | $147 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 17 | $46,885 | None |
| Injection, palonosetron hcl, 25 mcg | 47 | $26,911 | None |
| Return visit (30+ min) | 151 | $25,183 | $89 |
| Injection, zoledronic acid (zometa), 1 mg | 12 | $18,999 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 75 | $17,041 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $16,488 | $90 |
| New patient visit (60+ min) | 87 | $15,406 | $177 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $14,160 | $175 |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $11,506 | $73 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $7,762 | $77 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $7,670 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $7,540 | $62 |
| Administration of chemotherapy into vein, each additional hour | 45 | $7,429 | $31 |
| Injection of drug or substance under skin or into muscle | 77 | $6,559 | $24 |
| Long return visit (40+ min) | 42 | $6,162 | $126 |
| Injection, fosaprepitant, 1 mg | 12 | $5,101 | None |
| Administration of additional new drug or substance into vein using push technique | 21 | $4,900 | $64 |
| Injection of additional new drug or substance into vein | 63 | $3,723 | $22 |
| Administration of chemotherapy into vein using push technique | 11 | $3,337 | $115 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $2,346 | $60 |
| Biopsy of bone marrow | 13 | $2,314 | $165 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $2,288 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 26 | $2,097 | $18 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 77 | $1,981 | $10 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,865 | $32 |
| Injection, paclitaxel, 30 mg | 18 | $1,781 | None |
| Injection, carboplatin, 50 mg | 25 | $1,666 | None |
| Irrigation of implanted venous access drug delivery device | 12 | $1,223 | $25 |
| Infusion into a vein for hydration, each additional hour | 12 | $818 | $15 |
| Infusion, normal saline solution , 1000 cc | 55 | $431 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 62 | $290 | None |
| Blood test, comprehensive group of blood chemicals | 18 | $255 | $11 |
| Injection, ranitidine hydrochloride, 25 mg | 25 | $236 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $137 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $115 | None |
| Infusion, normal saline solution, 250 cc | 52 | $38 | None |
| Insertion of needle into vein for collection of blood sample | 11 | $35 | $3 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 34 | $27 | None |
| Injection, magnesium sulfate, per 500 mg | 12 | $16 | None |
Medicaid work
$277 in 2024
Medicaid paid $277 for 16 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 16 | $277 |
| 2024 | 16 | 1 | 13 | $277 |
| 2023 | 127 | 2 | 17 | $4,647 |
| 2022 | 32 | 2 | 16 | $1,012 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 113 | $4,406 |
| Return visit (30+ min) | 14 | $240 |
2022
| Long return visit (40+ min) | 19 | $724 |
| Return visit (30+ min) | 13 | $287 |
Drugs they prescribed that Part D paid
$1,282,013
Pharmacies billed $1,282,013 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 442) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
332 generic and 110 brand-name prescriptions · $1,282,013 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cabometyx | 12 | $307,856 | $25,655 |
| Verzenio | 13 | $190,984 | $14,691 |
| Lonsurf | 11 | $168,451 | $15,314 |
| Jakafi | 14 | $155,696 | $11,121 |
| Xarelto | 13 | $9,428 | $725 |
See all 13 drugs
| Cabometyx | 12 | $307,856 | $25,655 |
| Verzenio | 13 | $190,984 | $14,691 |
| Lonsurf | 11 | $168,451 | $15,314 |
| Jakafi | 14 | $155,696 | $11,121 |
| Xarelto | 13 | $9,428 | $725 |
| Exemestane | 24 | $5,212 | $217 |
| Letrozole | 139 | $3,575 | $26 |
| Hydroxyurea | 11 | $473 | $43 |
| Anastrozole | 15 | $325 | $22 |
| Dexamethasone | 27 | $188 | $7 |
| Tamoxifen Citrate | 17 | $181 | $11 |
| Ondansetron Odt | 22 | $156 | $7 |
| Ondansetron | 22 | $71 | $3 |
Year by year
| 2024 | 442 | 133 | 0% (0) | 25% | $1,282,013 |
| 2023 | 464 | 135 | 0% (0) | 25% | $1,505,838 |
| 2022 | 502 | 133 | None | 30% | $1,592,853 |
| 2021 | 493 | 127 | None | 42% | $1,754,220 |
| 2020 | 511 | 131 | None | 38% | $1,468,801 |
| 2019 | 595 | 155 | None | 32% | $1,270,264 |
| 2018 | 922 | 188 | 4% (32) | 23% | $1,295,940 |
| 2017 | 858 | 155 | 3% (29) | 27% | $1,457,788 |
| 2016 | 741 | 131 | 4% (28) | 28% | $1,188,539 |
| 2015 | 710 | 122 | 4% (26) | 24% | $783,983 |
| 2014 | 672 | 128 | 4% (24) | 19% | $543,248 |
| 2013 | 591 | 107 | 7% (43) | 17% | $267,314 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Cabometyx | 12 | $320,849 | $26,737 |
| Verzenio | 16 | $268,675 | $16,792 |
| Ibrance | 11 | $183,155 | $16,650 |
| Calquence | 12 | $172,075 | $14,340 |
| Everolimus | 12 | $121,520 | $10,127 |
| Xarelto | 16 | $13,751 | $859 |
| Eliquis | 17 | $10,232 | $602 |
| Letrozole | 98 | $5,858 | $60 |
| Exemestane | 14 | $2,304 | $165 |
| Tamoxifen Citrate | 19 | $614 | $32 |
| Ondansetron Odt | 37 | $483 | $13 |
| Hydroxyurea | 14 | $402 | $29 |
| Dexamethasone | 36 | $388 | $11 |
| Ondansetron | 30 | $253 | $8 |
| Allopurinol | 14 | $155 | $11 |
| Prednisone | 17 | $92 | $5 |
2022: 16 drugs
| Jakafi | 14 | $336,720 | $24,051 |
| Revlimid | 20 | $311,010 | $15,550 |
| Calquence | 12 | $168,148 | $14,012 |
| Xarelto | 26 | $24,585 | $946 |
| Eliquis | 28 | $15,850 | $566 |
| Exemestane | 24 | $6,611 | $275 |
| Letrozole | 60 | $2,297 | $38 |
| Tamoxifen Citrate | 32 | $754 | $24 |
| Ondansetron Odt | 40 | $489 | $12 |
| Anastrozole | 15 | $403 | $27 |
| Ondansetron | 24 | $321 | $13 |
| Dexamethasone | 33 | $290 | $9 |
| Lidocaine-Prilocaine | 14 | $220 | $16 |
| Allopurinol | 16 | $136 | $9 |
| Venlafaxine Hcl Er | 11 | $75 | $7 |
| Prednisone | 17 | $61 | $4 |
2021: 14 drugs
| Revlimid | 53 | $656,368 | $12,384 |
| Xtandi | 22 | $282,299 | $12,832 |
| Jakafi | 15 | $240,036 | $16,002 |
| Xarelto | 24 | $21,761 | $907 |
| Eliquis | 31 | $18,863 | $608 |
| Letrozole | 74 | $4,074 | $55 |
| Exemestane | 19 | $3,032 | $160 |
| Tamoxifen Citrate | 19 | $1,092 | $57 |
| Anastrozole | 14 | $520 | $37 |
| Dexamethasone | 46 | $470 | $10 |
| Allopurinol | 13 | $257 | $20 |
| Ondansetron | 27 | $223 | $8 |
| Acyclovir | 13 | $215 | $17 |
| Prednisone | 12 | $54 | $4 |
2020: 16 drugs
| Revlimid | 45 | $516,655 | $11,481 |
| Jakafi | 12 | $207,279 | $17,273 |
| Verzenio | 11 | $141,011 | $12,819 |
| Eliquis | 27 | $17,996 | $667 |
| Xarelto | 24 | $12,459 | $519 |
| Exemestane | 18 | $9,172 | $510 |
| Letrozole | 54 | $1,646 | $30 |
| Hydroxyurea | 20 | $1,133 | $57 |
| Tamoxifen Citrate | 14 | $1,018 | $73 |
| Acyclovir | 37 | $867 | $23 |
| Dexamethasone | 40 | $771 | $19 |
| Ondansetron Odt | 20 | $382 | $19 |
| Allopurinol | 19 | $235 | $12 |
| Prochlorperazine Maleate | 19 | $233 | $12 |
| Prednisone | 15 | $207 | $14 |
| Lidocaine-Prilocaine | 12 | $178 | $15 |
2019: 19 drugs
| Jakafi | 31 | $355,918 | $11,481 |
| Xtandi | 18 | $219,774 | $12,210 |
| Verzenio | 12 | $143,185 | $11,932 |
| Eliquis | 40 | $19,412 | $485 |
| Exemestane | 21 | $9,984 | $475 |
| Letrozole | 68 | $2,240 | $33 |
| Tamoxifen Citrate | 33 | $1,622 | $49 |
| Hydroxyurea | 25 | $866 | $35 |
| Warfarin | 31 | $680 | $22 |
| Ondansetron Odt | 40 | $563 | $14 |
| Allopurinol | 27 | $414 | $15 |
| Droxia | 17 | $394 | $23 |
| Anastrozole | 13 | $319 | $25 |
| Acyclovir | 15 | $306 | $20 |
| Lidocaine-Prilocaine | 11 | $194 | $18 |
| Ondansetron | 13 | $161 | $12 |
| Prednisone | 21 | $155 | $7 |
| Dexamethasone | 21 | $143 | $7 |
| Prochlorperazine Maleate | 12 | $119 | $10 |
2018: 21 drugs
| Jakafi | 39 | $435,428 | $11,165 |
| Xtandi | 15 | $170,218 | $11,348 |
| Eliquis | 59 | $35,563 | $603 |
| Exemestane | 40 | $14,464 | $362 |
| Enoxaparin | 25 | $10,143 | $406 |
| Letrozole | 97 | $2,660 | $27 |
| Tamoxifen Citrate | 70 | $2,498 | $36 |
| Hydroxyurea | 67 | $1,977 | $30 |
| Anastrozole | 45 | $1,063 | $24 |
| Allopurinol | 41 | $833 | $20 |
| Valacyclovir | 11 | $583 | $53 |
| Warfarin | 27 | $524 | $19 |
| Ondansetron | 25 | $497 | $20 |
| Acyclovir | 23 | $464 | $20 |
| Dexamethasone | 49 | $457 | $9 |
| Ondansetron Odt | 25 | $325 | $13 |
| Prednisone | 40 | $310 | $8 |
| Lidocaine-Prilocaine | 11 | $230 | $21 |
| Oxycodone | 15 | $158 | $11 |
| Alendronate | 13 | $110 | $8 |
| Prochlorperazine Maleate | 15 | $94 | $6 |
2017: 18 drugs
| Jakafi | 38 | $412,947 | $10,867 |
| Zytiga | 30 | $290,933 | $9,698 |
| Xtandi | 24 | $255,319 | $10,638 |
| Exemestane | 43 | $17,087 | $397 |
| Eliquis | 31 | $17,053 | $550 |
| Letrozole | 108 | $2,810 | $26 |
| Tamoxifen Citrate | 67 | $2,270 | $34 |
| Hydroxyurea | 40 | $1,655 | $41 |
| Anastrozole | 57 | $1,205 | $21 |
| Allopurinol | 74 | $898 | $12 |
| Valacyclovir | 11 | $646 | $59 |
| Prednisone | 42 | $547 | $13 |
| Acyclovir | 23 | $437 | $19 |
| Dexamethasone | 29 | $271 | $9 |
| Hydrocodone-Acetaminophen | 11 | $178 | $16 |
| Alendronate | 19 | $154 | $8 |
| Lorazepam | 18 | $92 | $5 |
| Pantoprazole | 11 | $59 | $5 |
2016: 21 drugs
| Jakafi | 26 | $276,004 | $10,616 |
| Xtandi | 21 | $195,146 | $9,293 |
| Revlimid | 14 | $162,862 | $11,633 |
| Zytiga | 17 | $146,513 | $8,618 |
| Ibrance | 13 | $134,323 | $10,333 |
| Exemestane | 37 | $15,951 | $431 |
| Xarelto | 19 | $8,737 | $460 |
| Eliquis | 18 | $8,495 | $472 |
| Letrozole | 78 | $2,164 | $28 |
| Tamoxifen Citrate | 73 | $1,796 | $25 |
| Hydroxyurea | 33 | $1,187 | $36 |
| Anastrozole | 57 | $1,158 | $20 |
| Allopurinol | 65 | $1,014 | $16 |
| Acyclovir | 22 | $593 | $27 |
| Hydrocodone-Acetaminophen | 18 | $485 | $27 |
| Prednisone | 23 | $406 | $18 |
| Dexamethasone | 24 | $271 | $11 |
| Pantoprazole | 12 | $174 | $15 |
| Ondansetron | 17 | $113 | $7 |
| Alendronate | 16 | $83 | $5 |
| Lorazepam | 12 | $76 | $6 |
2015: 18 drugs
| Jakafi | 22 | $214,216 | $9,737 |
| Xtandi | 19 | $171,632 | $9,033 |
| Zytiga | 18 | $139,721 | $7,762 |
| Gleevec | 13 | $122,110 | $9,393 |
| Exemestane | 37 | $12,796 | $346 |
| Enoxaparin | 15 | $9,194 | $613 |
| Xarelto | 23 | $7,447 | $324 |
| Tamoxifen Citrate | 65 | $1,931 | $30 |
| Hydroxyurea | 40 | $1,214 | $30 |
| Letrozole | 76 | $1,169 | $15 |
| Anastrozole | 72 | $932 | $13 |
| Allopurinol | 23 | $417 | $18 |
| Prednisone | 34 | $406 | $12 |
| Valacyclovir | 11 | $362 | $33 |
| Pantoprazole | 27 | $309 | $11 |
| Hydrocodone-Acetaminophen | 11 | $287 | $26 |
| Alendronate | 37 | $218 | $6 |
| Ondansetron | 15 | $117 | $8 |
2014: 17 drugs
| Zytiga | 21 | $153,363 | $7,303 |
| Xarelto | 31 | $9,057 | $292 |
| Exemestane | 18 | $7,755 | $431 |
| Anastrozole | 52 | $1,670 | $32 |
| Tamoxifen Citrate | 52 | $1,458 | $28 |
| Letrozole | 63 | $1,404 | $22 |
| Hydroxyurea | 43 | $1,319 | $31 |
| Valacyclovir | 16 | $703 | $44 |
| Pantoprazole | 26 | $407 | $16 |
| Ondansetron | 27 | $319 | $12 |
| Prednisone | 25 | $299 | $12 |
| Allopurinol | 22 | $249 | $11 |
| Alendronate | 25 | $234 | $9 |
| Dexamethasone | 21 | $168 | $8 |
| Acyclovir | 16 | $144 | $9 |
| Prochlorperazine Maleate | 21 | $123 | $6 |
| Ciprofloxacin | 15 | $111 | $7 |
2013: 19 drugs
| Enoxaparin | 11 | $13,047 | $1,186 |
| Creon | 12 | $1,886 | $157 |
| Anastrozole | 33 | $1,460 | $44 |
| Letrozole | 31 | $1,337 | $43 |
| Hydroxyurea | 40 | $1,274 | $32 |
| Tamoxifen Citrate | 29 | $1,014 | $35 |
| Pantoprazole | 29 | $445 | $15 |
| Dexamethasone | 43 | $381 | $9 |
| Warfarin | 23 | $379 | $16 |
| Lidocaine-Prilocaine | 11 | $362 | $33 |
| Acyclovir | 17 | $275 | $16 |
| Oxycodone | 15 | $249 | $17 |
| Hydrocodone-Acetaminophen | 12 | $215 | $18 |
| Ondansetron | 15 | $197 | $13 |
| Prochlorperazine Maleate | 29 | $164 | $6 |
| Allopurinol | 22 | $159 | $7 |
| Famotidine | 17 | $128 | $8 |
| Metoprolol | 12 | $96 | $8 |
| Lorazepam | 16 | $62 | $4 |
Money from drug and device companies
$129 in 2024
| 2024 | 1 | 1 | None | $129 |
| 2023 | 3 | 3 | None | $87 |
| 2021 | 1 | 1 | None | $14 |
| 2020 | 2 | 3 | None | $47 |
| 2019 | 10 | 12 | None | $244 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $129 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Meals · 2024-12-18 | Lynparza | $129 |
See earlier years (2023, 2021, 2020, 2019)
2023: $87
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $42 | 1 payment
|
| Foundation Medicine | None | $30 | 1 payment
|
| Pfizer | Ibrance | $14 | 1 payment
|
2021: $14
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
2020: $47
| Eisai | Lenvima | $26 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $21 | 1 payment
|
2019: $244
| Novartis Pharmaceuticals | Promacta | $46 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $31 | 2 payments
|
| Genzyme | Libtayo | $24 | 1 payment
|
| Janssen Biotech | Erleada | $23 | 1 payment
|
| Lilly USA | Alimta | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $22 | 1 payment
|
| Tactile Systems Technology | Flexitouch | $21 | 1 payment
|
| Amgen | Kyprolis | $21 | 1 payment
|
| Tesaro | Zejula | $19 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Empliciti | $16 | 1 payment
|
Professional record
- NPI
- 1114925542
- Licence
- CA C53848California C53848: Current · expires 2027-02-28
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2589 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2005-07-10
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.